PDCD1 and neoplasm: In this paper, we first screened 23 different syngeneic tumor models treated with anti-PD-1 and found that two colorectal carcinoma CT-26 and Colon 26 tumor models shared similar genetic background but exhibited different sensitivity to anti-PD-1 therapies.